Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07506681

IMAT Quality in Aging

This study will test the central hypothesis that fat within the muscle, or intramuscular adipose tissue (IMAT), exhibits elevated damage and pro-inflammatory signaling with aging, both of which are reduced by progressive resistance exercise (PRE). Sixteen older adults 65-80 years old will be recruited and complete a 12 week calf PRE intervention. Calf muscle strength, composition (measured by computed tomography) and muscle biopsies will be collected before and after the intervention. Histology, transcriptomic and secretomic tests will be completed to assess signs of damage and inflammation.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

65 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Washington University

St Louis, Missouri, 63108, United States

Location contact

Gretchen Meyer, PhD

PRINCIPAL_INVESTIGATOR

Mary Hastings, PT, DPT, MSCI, ATC

CONTACT

[email protected]

314-286-1433

Mary Hastings, PT, DPT, MSCI, ATC

SUB_INVESTIGATOR

CONTACT

[email protected]

About this study

Sixteen older adult (65-80 years) will be recruited from existing databases and screened for potential participation by phone. The Rapid Assessment of Physical Activity (RAPA) will be completed, to include those who are underactive (scores 3-5). Individuals who meet the inclusion criteria will attend an in-person screening where their calf muscle strength, physical performance and safety for muscle biopsy (via complete blood count with differential and prothrombin time/international normalized raio on blood draw) will be assessed. Individuals deemed safe to participate and who give informed consent will attend a second visit which will include a computed tomography (CT) scan of the lower leg and ultrasound-guided gastrocnemius muscle+IMAT biopsy. One week later, participants will begin the ankle plantarflexor-targeted progressive resistance exercise (PRE) program which will be delivered in a group Zoom format with a trained therapist 3 times per week for 12 weeks. One week following completion of the PRE program, participants will return for follow-up strength measures, CT, and biopsy. This will complete their participation. In the lab, biopsies will be subdivided for bulk ribonucleic acid sequencing (RNAseq), explant culture and histology. Bulk RNAseq will be used to identify age- and exercise-responsive genes that encode secreted proteins. These putative secreted signals will be validated by protein quantification in explant culture. The cellular origin of validated signals will then be mapped by RNA in situ hybridization (RNAscope) on the portion of the biopsy allocated to histology. Sections will also used to identify senescent cells, inflammatory macrophages and beige adipocytes.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Rapid Assessment of Physical Activity scores between 3 and 5
  • Able to don and doff the weighted vest
  • Access to a smart phone and ability to navigate the phone to enter and manage a zoom intervention
  • Commitment and availability to attend a virtual 40-minute intervention 3x per week for 12 weeks

Exclusion criteria

  • Contraindications to radiation exposure (e.g. Women who are pregnant, previous high radiation exposure)
  • Bleeding disorders
  • Lower extremity trauma/surgery/injury or neuropathy that would impact muscle structure and function or ability to complete exercise intervention
  • Diabetes mellitus, cardiovascular disease, peripheral vascular disease, cancer, stage 4 hypertension, anemia, connective tissue disorder
  • Neurological disorder (e.g. stroke, Parkinson's disease, multiple sclerosis, spinal cord injury)
  • Medications: insulin, glucagon-like peptide-1 (GLP1) agonists, sex hormone replacement therapy, chronic NSAIDs, anticoagulation therapy, cholesterol lowering medications such as statins
  • Unable to safely perform the progressive resistance exercise (e.g. Vestibular or balance issues that make performing the intervention unsafe, severe osteoporosis or general fragility that limits weighted vest tolerance)

Treatment and study plan

Calf muscle strengthening

Other

The calf intervention will be delivered 3x/wk for 12 weeks over zoom, in small groups. There are 3 exercises 1) standing heel rise, 2) seated heel rise, and 3) long sitting ankle plantarflexion. The exercises will be overloaded using a weighted vest, body weight, and/or theraband. Exercises will be progressed as strength improves.

Primary outcomes

  1. Biopsy: Senescent cell density

    Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)

    Senescent cells will be identified by expression of β-galactosidase (b-gal) and p16 on histological sections from muscle biopsies. B-gal and p16 positive cells will be counted and normalized to the histological region of interest to obtain a measure of density (# senescent cells / mm^2).

Secondary outcomes

  1. Total plantarflexor muscle volume (CT) (Cm^3)

    Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)

    Muscle volume of the calf and foot will be measured with computed tomography (CT). The participant is supine with leg extended into the (CT). Image post-processing includes removing bones and subcutaneous fat and then segmenting and measuring plantarflexor compartment muscle volume (cm^3).

  2. Plantarflexor Compartment Intramuscular Fat Volume (cm^3)

    Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)

    Intramuscular fat volume of the calf will be measured with computed tomography (CT). The participant is supine with leg extended into the (CT). Image post-processing includes removing bones and subcutaneous fat and then segmenting and measuring plantarflexor compartment fat volume (cm^3).

  3. Plantarflexor peak torque (Newton-meters)

    Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)

    Plantarflexor peak torque of the ankle will be assessed using isokinetic dynamometry. The participant will have a minimum of 3 practice trials to become familiar with the test. The participant will be given 3 minutes of rest and then 3 maximum plantarflexion contractions will be completed, the highest torque produced will be recorded (Newton-meters, Nm).

  4. Stair Climb Power (W)

    Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)

    Stair climb power will be calculated by multiplying the participant's weight (N)X height of stairs (1.853 meters)/time is takes for them to climb the 10 steps.

  5. Walking Speed (meters/second)

    Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)

    50 foot walking speed (meters/sec) will be measured. Route is 25 feet to a line, turn around, and return to start.

  6. Physical Performance Test Total Score

    Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)

    Physical performance test total score is a composite from the following tests: bilateral feet together stance time, bilateral semi-tandem stance time, and bilateral tandem stance time, five time chair rise time, lift a book to a shelf time, don and doff a jacket time, 360 turn right and left examining stability and continuity, time to pick a nickle off the floor, 50 feet walking speed, stair climb speed. Score ranges from 32 (no fraility) to 0 (severe frailty)

  7. Biopsy: Adipocyte size

    Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)

    Adipocyte boundaries will be identified by expression of perilipin on histological sections from muscle biopsies. Adipocyte area will be defined as the area inside a perilipin bounded shape and will be quantified for each adipocyte in the histological region of interest (mm^2).

  8. Biopsy: Macrophage density

    Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)

    Macrophages will be identified by expression of CD206 and CD68 on histological sections from muscle biopsies. CD206 and CD68 positive cells will be counted and normalized to the histological region of interest to obtain a measure of density (# senescent cells / mm^2).

  9. Biopsy: Beige adipocyte density

    Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)

    Beige adipocytes will be identified by expression of UCP1 on histological sections from muscle biopsies. UCP1 positive cells will be counted and normalized to the histological region of interest to obtain a measure of density (# senescent cells / mm^2).

  10. Biopsy: Differentially expressed genes and pathways

    Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)

    Differentially expressed genes and pathways will be extracted from RNA sequencing performed on biopsy material (gene count).

  11. Biopsy: cytokine secretion

    Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)

    Cytokines will be analyzed in the secreted medium from biopsy material using an antibody based detection method (pg/mL).

  12. Biopsy: Spatially resolved gene expression

    Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)

    Spatially resolved gene expression will be measured on histological sections using an RNAscope (dots/cell).

Study contacts

Contact information is provided by the study sponsor or research team.

Gretchen Meyer, PhD

CONTACT

[email protected]

1-314-286-1456

Mary Hastings, PT, DPT, MSCI, ATC

CONTACT

[email protected]

1 314-286-1433

Sponsors and collaborators

Lead sponsor

Washington University School of Medicine

Other

Collaborators

  • National Institute on Aging (NIA)

Registry information

Official study title

Targeting Intramuscular Adipose Quality in Aging

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Apr 2, 2026
Registry last updated
Apr 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.